FY2025 · ended Dec 31, 2025 · Revenue $6.94M, -23.2% YoY · Filed Mar 3, 2026
Immunome, Inc. (IMNM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $6.9 million and a net loss of $212.4 million. Free cash flow was -$200.6 million. As of Jun 30, 2026 it held $520.0 million in cash and investments and $4.7 million in total debt.
Revenue (TTM)
$0
-100.0% vs year-ago TTM
Net income (TTM)
$-254.32M
-19.7% vs year-ago TTM
Operating cash flow (TTM)
$-208.79M
-16.9% vs year-ago TTM
Free cash flow (TTM)
$-219.09M
-17.8% vs year-ago TTM
EPS (TTM)
$-2.49
+15.3% vs year-ago TTM
Dividend per share
None
Shares outstanding
113.13M
+30.1% vs prior year
Net cash
$515.26M
as of Jun 30, 2026
Operating margin
-3228.8%
FY 2025
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- IMNM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Bothell, WA
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1472012
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M |
| Net income | -$212.4M | -$293.0M | -$106.8M | -$36.9M | -$24.7M |
| Diluted EPS | -$2.43 | -$5.00 | -$5.38 | -$3.09 | -$2.14 |
| Operating cash flow | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M |
| Free cash flow | -$200.6M | -$118.0M | -$8.4M | -$28.9M | -$18.3M |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M |
| Stockholders' equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M |
| Cash and investments | $653.5M | $217.3M | $138.1M | $20.3M | $49.2M |
| Total debt | $3.9M | $4.8M | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 5, 2026 | Oct 2, 2026 |
| 10-Q | Quarterly report | Aug 11, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 9, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 12, 2026 | May 12, 2026 |
All 460 Immunome, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.